Maria Drakopoulou*, Stergios Soulaidopoulos, Konstantinos Stathogiannis, Georgios Oikonomou, Aggelos Papanikolaou, Konstantinos Toutouzas and Dimitrios Tousoulis Pages 2769 - 2779 ( 11 )
Pathologies of the atrial septum include different interatrial communications varying from patent foramen ovale (PFO) to actual defects. Atrial septal defects (ASDs) may be localized within the fossa ovalis such as the secundum type ASD or outside the region of fossa ovalis, such as the ostium primum defect and sinus venosus defect. Over the last decades, the percutaneous closure of interatrial shunts has become a feasible and safe method. During these procedures, the delicate balance between thrombotic risk, device sealing process and bleeding risk is crucial. In this review, we sought to describe current available data on the antiplatelet and antithrombotic management of patients after percutaneous ASD or PFO closure.
Patent foramen ovale, atrial septal defect, occluder devices, structural heart disease, fossa ovalis, interatrial shunts.
First Department of Cardiology, Hippokration Hospital, Medical School of Athens University, Athens, First Department of Cardiology, Hippokration Hospital, Medical School of Athens University, Athens, First Department of Cardiology, Hippokration Hospital, Medical School of Athens University, Athens, First Department of Cardiology, Hippokration Hospital, Medical School of Athens University, Athens, First Department of Cardiology, Hippokration Hospital, Medical School of Athens University, Athens, First Department of Cardiology, Hippokration Hospital, Medical School of Athens University, Athens, First Department of Cardiology, Hippokration Hospital, Medical School of Athens University, Athens